Anti-Delta Opioid Receptor antibody [EPR5029(2)]

• ICC/IF

Lab

Immunocytochemistry/ Immunofluorescence - Anti-Delta Opioid Receptor antibody [EPR5029(2)] (AB176324)

Immunocytochemistry/Immunofluorescence analysis of SH-SY5Y cells labelling Delta Opioid Receptor at 1/500. Cells were fixed with 100% Methanol. An ab150077 AlexaFluor®488 Goat anti-Rabbit secondary (1/1000) was used as the secondary antibody. Nuclei counterstained with DAPI (blue).

Control : primary antibody (1/500) and secondary antibody, ab150077 AlexaFluor®488 Goat anti-Rabbit secondary IgG (1/1000).

• Flow Cyt (Intra)

Unknown

Flow Cytometry (Intracellular) - Anti-Delta Opioid Receptor antibody [EPR5029(2)] (AB176324)

Flow Cytometry analysis of U-87 MG (Human glioblastoma-astrocytoma epithelial cell) cells labeling Delta Opioid Receptor with purified ab176324 at 1/150 dilution (10 µg/ml) (Red). Cells were fixed with 4% Paraformaldehyde and permeabilised with 90% Methanol. A Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) secondary antibody was used at 1/2000. Isotype control - Rabbit monoclonal IgG (Black). Unlabeled control - Cell without incubation with primary antibody and secondary antibody (Blue).

• Flow Cyt (Intra)

Supplier Data

Flow Cytometry (Intracellular) - Anti-Delta Opioid Receptor antibody [EPR5029(2)] (AB176324)

Flow cytometric analysis of U87-MG cells labeling Delta Opioid Receptor using ab176324 at a 1/10 dilution (red) or a rabbit IgG control (green).

• ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-Delta Opioid Receptor antibody [EPR5029(2)] (AB176324)

Immunocytochemistry/ Immunofluorescence analysis of SH-SY5Y (Human neuroblastoma epithelial cell) cells labeling Delta Opioid Receptor with purified ab176324 at 1/100 dilution (10 µg/ml). Cells were fixed in 100% Methanol and permeabilized with None. Cells were counterstained with ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) 1/200 (2.5 µg/ml). Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) was used as the secondary antibody at 1/1000 (2 µg/ml) dilution. DAPI (blue) was used as nuclear counterstain. PBS instead of the primary antibody was used as the secondary antibody only control.

• WB

Lab

Western blot - Anti-Delta Opioid Receptor antibody [EPR5029(2)] (AB176324)

All lanes:

Western blot - Anti-Delta Opioid Receptor antibody [EPR5029(2)] (ab176324) at 1/2000 dilution

Lane 1:

Human brain lysates at 20 µg

Lane 2:

Mouse spleen lysates at 20 µg

Lane 3:

Rat spleen lysates at 20 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution

Predicted band size: 40 kDa

Observed band size: 40 kDa

false

• WB

Supplier Data

Western blot - Anti-Delta Opioid Receptor antibody [EPR5029(2)] (AB176324)

All lanes:

Western blot - Anti-Delta Opioid Receptor antibody [EPR5029(2)] (ab176324) at 1/1000 dilution

Lane 1:

Human cerebellum lysate at 10 µg

Lane 2:

Human fetal brain lysate at 10 µg

Lane 3:

U87-MG lysate at 10 µg

Lane 4:

HUVEC lysate at 10 µg

Lane 5:

SH-SY5Y lysate at 10 µg

Predicted band size: 40 kDa

false

• WB

Lab

Western blot - Anti-Delta Opioid Receptor antibody [EPR5029(2)] (AB176324)

All lanes:

Western blot - Anti-Delta Opioid Receptor antibody [EPR5029(2)] (ab176324) at 1/10000 dilution

All lanes:

Mouse brain lysates at 20 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution

Predicted band size: 40 kDa

Observed band size: 40 kDa

false

• WB

CiteAb

Western blot - Anti-Delta Opioid Receptor antibody [EPR5029(2)] (AB176324)

Delta Opioid Receptor western blot using anti-Delta Opioid Receptor antibody [EPR5029(2)] ab176324. Publication image and figure legend from Leoncikas, V., Wu, H., et al., 2016, Sci Rep, PubMed 26813959.

ab176324 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab176324 please see the product overview.

Deregulated casomorphin metabolism is a metabolic feature of poor patient prognosis tumours but is not associated with enhanced cell viability in vitro.(a) Personalized GSMNs were derived from the 997 patient transcriptome profiles within the Metabric discovery set. Comparison of the 134 personalized GSMNs associated with poor patient with the remaining 863 personalized reveals casomorphin degradation as a major driver for this separation, through increased ACE2 expression (E.C. 3.4.17.23, indicated in red). Exposure of breast cancer cell lines with the ACE2 inhibitor DX600, or β-casomorphin had no significant impact on cell proliferation. (b) Expression of network components (ACE2, MOR, DOR and KOR) in breast cancer cell lines. (c) Pharmacological perturbation of proposed network for 72h in MCF7, SKBR3 and T47D cell lines has not significant impact on the cell proliferation rate. Results are expressed as a percentage of vehicle control; each data point represents the mean of a minimum of three independent experiments of 3 wells per experiment, with error bars representing the standard error of the mean (SEM).

false